Skip to main content

SYSTEMATIC REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1435127
This article is part of the Research Topic Transplantation and Cellular Therapy in Lymphomas and Plasma Cell Disorders View all 16 articles

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis

Provisionally accepted
Haixiang Wan Haixiang Wan Songqin Weng Songqin Weng Sumei Sheng Sumei Sheng Zilin Kuang Zilin Kuang Qingming Wang Qingming Wang Linhui Hu Linhui Hu *
  • Second Affiliated Hospital of Nanchang University, Nanchang, China

The final, formatted version of the article will be published soon.

    Background: Chimeric antigen receptor (CAR) T-cell therapy (CAR-T therapy) has demonstrated significant efficacy in the ZUMA-2 study. After regulatory approvals, several clinical trials and real-world studies on CAR-T therapy for relapsed or refractory mantle cell lymphoma (R/R MCL) were conducted. However, data on clinical safety and efficacy are inconsistent. In this study, we aimed to conduct a systematic analysis of the effectiveness and safety of CAR-T therapy across a wider and more representative cohort of patients with R/R MCL.We performed a systematic review and meta-analysis of studies on patients with R/R MCL who received CAR-T cell therapy. Data were extracted and consolidated, with primary focus on the evaluation of safety and efficacy outcome measures. This study has not been registered with PROSPERO.Results: This meta-analysis identified and included 16 studies with 984 patients. The pooled estimate for overall response rate (ORR) was 89%; complete remission (CR) rate was 74%. The 6-month and 12-month progression-free survival (PFS) rates were 69% and 53%, respectively, while the overall survival (OS) rates were 80% and 69%, respectively. Cytokine release syndrome (CRS) of grade 3 or higher was observed in 8% of patients, whereas neurotoxicity of grade 3 or higher was observed in 22% of patients.The risk of bias was assessed as low in 9 studies and moderate in 7 studies.CAR-T therapy exhibited promising efficacy and manageable adverse reactions in patients with R/R MCL.

    Keywords: car-t, Relapsed or refractory, Mantle cell lymphoma, Meta-analysis, therapy

    Received: 19 May 2024; Accepted: 12 Aug 2024.

    Copyright: © 2024 Wan, Weng, Sheng, Kuang, Wang and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Linhui Hu, Second Affiliated Hospital of Nanchang University, Nanchang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.